201 related articles for article (PubMed ID: 16952140)
1. Correlation of biological activity with active site binding modes of geminal disulfone HIV-1 integrase inhibitors.
Meadows DC; Tantillo DJ; Gervay-Hague J
ChemMedChem; 2006 Sep; 1(9):959-64. PubMed ID: 16952140
[No Abstract] [Full Text] [Related]
2. Synthesis and biological evaluation of geminal disulfones as HIV-1 integrase inhibitors.
Meadows DC; Mathews TB; North TW; Hadd MJ; Kuo CL; Neamati N; Gervay-Hague J
J Med Chem; 2005 Jul; 48(14):4526-34. PubMed ID: 15999991
[TBL] [Abstract][Full Text] [Related]
3. A platform for designing HIV integrase inhibitors. Part 2: a two-metal binding model as a potential mechanism of HIV integrase inhibitors.
Kawasuji T; Fuji M; Yoshinaga T; Sato A; Fujiwara T; Kiyama R
Bioorg Med Chem; 2006 Dec; 14(24):8420-9. PubMed ID: 17005407
[TBL] [Abstract][Full Text] [Related]
4. Triketoacid inhibitors of HIV-integrase: a new chemotype useful for probing the integrase pharmacophore.
Walker MA; Johnson T; Ma Z; Banville J; Remillard R; Kim O; Zhang Y; Staab A; Wong H; Torri A; Samanta H; Lin Z; Deminie C; Terry B; Krystal M; Meanwell N
Bioorg Med Chem Lett; 2006 Jun; 16(11):2920-4. PubMed ID: 16546383
[TBL] [Abstract][Full Text] [Related]
5. Salicylhydrazine-containing inhibitors of HIV-1 integrase: implication for a selective chelation in the integrase active site.
Neamati N; Hong H; Owen JM; Sunder S; Winslow HE; Christensen JL; Zhao H; Burke TR; Milne GW; Pommier Y
J Med Chem; 1998 Aug; 41(17):3202-9. PubMed ID: 9703465
[TBL] [Abstract][Full Text] [Related]
6. A platform for designing HIV integrase inhibitors. Part 1: 2-hydroxy-3-heteroaryl acrylic acid derivatives as novel HIV integrase inhibitor and modeling of hydrophilic and hydrophobic pharmacophores.
Kawasuji T; Yoshinaga T; Sato A; Yodo M; Fujiwara T; Kiyama R
Bioorg Med Chem; 2006 Dec; 14(24):8430-45. PubMed ID: 17010623
[TBL] [Abstract][Full Text] [Related]
7. Symmetrical 1-pyrrolidineacetamide showing anti-HIV activity through a new binding site on HIV-1 integrase.
Du L; Zhao YX; Yang LM; Zheng YT; Tang Y; Shen X; Jiang HL
Acta Pharmacol Sin; 2008 Oct; 29(10):1261-7. PubMed ID: 18817633
[TBL] [Abstract][Full Text] [Related]
8. Dissecting Tn5 transposition using HIV-1 integrase diketoacid inhibitors.
Czyz A; Stillmock KA; Hazuda DJ; Reznikoff WS
Biochemistry; 2007 Sep; 46(38):10776-89. PubMed ID: 17725323
[TBL] [Abstract][Full Text] [Related]
9. Crystal structure of the HIV-1 integrase core domain in complex with sucrose reveals details of an allosteric inhibitory binding site.
Wielens J; Headey SJ; Jeevarajah D; Rhodes DI; Deadman J; Chalmers DK; Scanlon MJ; Parker MW
FEBS Lett; 2010 Apr; 584(8):1455-62. PubMed ID: 20227411
[TBL] [Abstract][Full Text] [Related]
10. Design and synthesis of substituted 4-oxo-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine-2-carboxamides, novel HIV-1 integrase inhibitors.
Langford HM; Williams PD; Homnick CF; Vacca JP; Felock PJ; Stillmock KA; Witmer MV; Hazuda DJ; Gabryelski LJ; Schleif WA
Bioorg Med Chem Lett; 2008 Jan; 18(2):721-5. PubMed ID: 18078751
[TBL] [Abstract][Full Text] [Related]
11. Design and optimization of tricyclic phtalimide analogues as novel inhibitors of HIV-1 integrase.
Verschueren WG; Dierynck I; Amssoms KI; Hu L; Boonants PM; Pille GM; Daeyaert FF; Hertogs K; Surleraux DL; Wigerinck PB
J Med Chem; 2005 Mar; 48(6):1930-40. PubMed ID: 15771437
[TBL] [Abstract][Full Text] [Related]
12. Analysis of binding parameters of HIV-1 integrase inhibitors: correlates of drug inhibition and resistance.
Loizidou EZ; Zeinalipour-Yazdi CD; Christofides T; Kostrikis LG
Bioorg Med Chem; 2009 Jul; 17(13):4806-18. PubMed ID: 19450984
[TBL] [Abstract][Full Text] [Related]
13. Synthesis, antiviral, and anti-HIV-1 integrase activities of 3-aroyl-1,1-dioxo-1,4,2-benzodithiazines.
Brzozowski Z; Saczewski F; Sanchez T; Kuo CL; Gdaniec M; Neamati N
Bioorg Med Chem; 2004 Jul; 12(13):3663-72. PubMed ID: 15186851
[TBL] [Abstract][Full Text] [Related]
14. Azaindole hydroxamic acids are potent HIV-1 integrase inhibitors.
Plewe MB; Butler SL; Dress KR; Hu Q; Johnson TW; Kuehler JE; Kuki A; Lam H; Liu W; Nowlin D; Peng Q; Rahavendran SV; Tanis SP; Tran KT; Wang H; Yang A; Zhang J
J Med Chem; 2009 Nov; 52(22):7211-9. PubMed ID: 19873974
[TBL] [Abstract][Full Text] [Related]
15. Synthesis of polyhydroxylated aromatics having amidation of piperazine nitrogen as HIV-1 integrase inhibitor.
Yang L; Xu X; Huang Y; Zhang B; Zeng C; He H; Wang C; Hu L
Bioorg Med Chem Lett; 2010 Sep; 20(18):5469-71. PubMed ID: 20709544
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and anti-integrase activity of catechol-DKA hybrids.
Maurin C; Bailly F; Mbemba G; Mouscadet JF; Cotelle P
Bioorg Med Chem; 2006 May; 14(9):2978-84. PubMed ID: 16412645
[TBL] [Abstract][Full Text] [Related]
17. Docking dinucleotides to HIV-1 integrase carboxyl-terminal domain to find possible DNA binding sites.
Zhu HM; Chen WZ; Wang CX
Bioorg Med Chem Lett; 2005 Jan; 15(2):475-7. PubMed ID: 15603976
[TBL] [Abstract][Full Text] [Related]
18. Exploration of novel thiobarbituric acid-, rhodanine- and thiohydantoin-based HIV-1 integrase inhibitors.
Rajamaki S; Innitzer A; Falciani C; Tintori C; Christ F; Witvrouw M; Debyser Z; Massa S; Botta M
Bioorg Med Chem Lett; 2009 Jul; 19(13):3615-8. PubMed ID: 19447621
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and biological evaluation of (E)-3,4-dihydroxystyryl 4-acylaminophenethyl sulfone, sulfoxide derivatives as dual inhibitors of HIV-1 CCR5 and integrase.
Sun Y; Xu W; Fan N; Sun X; Ning X; Ma L; Liu J; Wang X
Bioorg Med Chem; 2017 Feb; 25(3):1076-1084. PubMed ID: 28082070
[TBL] [Abstract][Full Text] [Related]
20. Crystal structures of novel allosteric peptide inhibitors of HIV integrase identify new interactions at the LEDGF binding site.
Rhodes DI; Peat TS; Vandegraaff N; Jeevarajah D; Newman J; Martyn J; Coates JA; Ede NJ; Rea P; Deadman JJ
Chembiochem; 2011 Oct; 12(15):2311-5. PubMed ID: 21850718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
